Cervical Carcinoma in Shatby University Hospital and Its Relation to Human Papilloma Virus
September 30, 2022 updated by: Hossam Hassan Aly Hassan El Sokkary
incidence of detection of carcinogenic types of human papilloma virus in 60 cases of cervical cancer
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Actual)
70
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Alexandria, Egypt
- Hossam Hassan El Sokkary
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- ADULT
- OLDER_ADULT
- CHILD
Accepts Healthy Volunteers
N/A
Genders Eligible for Study
Female
Sampling Method
Non-Probability Sample
Study Population
cervical cancer cases
Description
Inclusion Criteria:
- cervical cancer
Exclusion Criteria:
- none
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
cervical cancer group, control group
|
an observational analytical prospective cross-sectional study was managed from July 2019 to July 2022 on 70 cervical cancer patients collected from gyne-oncology unit in Shatby obstetrics and gynecology university hospital of Alexandria medical school after taking a written consent and following approval by Alexandria medical school institutional ethics committee.
All patients were subjected to full history taking as age, gravidity, parity, contraceptive history, medical disease, detailed marital history and smoking.
Collection of the sample from all cases of the study for human papilloma virus testing and genotyping was done after diagnostic workup and before treatment of the study cases at any time in post-menopausal women and at mid cycles period in premenopausal women by cervical smear using PAP spatula and endocervical brush.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Detection of human papilloma virus infections and genotyping using real time PCR
Time Frame: 10 days
|
10 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
July 1, 2019
Primary Completion (ACTUAL)
June 1, 2022
Study Completion (ACTUAL)
July 31, 2022
Study Registration Dates
First Submitted
September 8, 2022
First Submitted That Met QC Criteria
September 9, 2022
First Posted (ACTUAL)
September 14, 2022
Study Record Updates
Last Update Posted (ACTUAL)
October 3, 2022
Last Update Submitted That Met QC Criteria
September 30, 2022
Last Verified
September 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Sokkary11
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.